Trails Edge Capital Partners, LP
Clone Performance
Feb 2026–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 99% of reported value on average across 3 quarters. Past performance does not predict future results.
Portfolio Concentration
35 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.2% | $624,561,875 |
| Financial Services | 0.8% | $5,350,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | +2,243,658 | 2,743,658 | $11,276,434 | |
| IPSC | Century Therapeutics, Inc. | +1,684,976 | 4,134,969 | $10,130,674 | |
| DSGN | Design Therapeutics, Inc. | +1,149,269 | 2,001,282 | $28,958,550 | |
| IKT | Inhibikase Therapeutics, Inc. | +993,973 | 9,051,318 | $18,374,175 | |
| FDMT | 4D Molecular Therapeutics, Inc. | +925,000 | 2,227,917 | $29,631,296 | |
| SNDX | Syndax Pharmaceuticals Inc | +408,179 | 1,110,000 | $24,264,600 | |
| FTH | Faeth Therapeutics, Inc. | +390,335 | 515,335 | $12,883,375 | |
| IMCR | Immunocore Holdings plc | +380,637 | 1,063,234 | $33,757,679 | |
| LBRX | Lb Pharmaceuticals Inc | +203,660 | 1,523,022 | $49,429,679 | |
| SLGL | Sol-Gel Technologies Ltd. | +53,949 | 139,445 | $10,338,452 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | −200,000 | 440,000 | $26,558,400 | |
| NRIX | Nurix Therapeutics, Inc. | −170,000 | 1,573,220 | $38,166,317 | |
| RVMD | Revolution Medicines, Inc. | −129,250 | 115,750 | $21,677,660 | |
| MIRM | Mirum Pharmaceuticals, Inc. | −110,000 | 223,312 | $26,143,135 | |
| NGNE | Neurogene Inc. | −67,902 | 714,885 | $22,483,133 | |
| VTVT | vTv Therapeutics Inc. | −54,386 | 85,192 | $3,207,478 | |
| CYTK | Cytokinetics Inc | −11,911 | 288,089 | $24,542,301 | |
| CAMP | Camp4 Therapeutics Corp | −6,626 | 1,932,937 | $8,446,934 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | 1,514,000 | $30,461,680 | |
| BMRN | Biomarin Pharmaceutical Inc | 512,000 | $29,296,640 | |
| INSM | INSMED Inc | 230,331 | $24,557,891 | |
| KLRA | Kailera Therapeutics, Inc. | 984,786 | $21,694,835 | |
| INCY | Incyte Corp | 155,000 | $17,570,800 | |
| AVTX | Avalo Therapeutics, Inc. | 891,881 | $16,481,960 | |
| MLTX | MoonLake Immunotherapeutics | 750,000 | $14,602,500 | |
| AURA | Aura Biosciences, Inc. | 1,443,333 | $10,247,664 | |
| ALT | Altimmune, Inc. | 2,660,000 | $8,086,400 | |
| OKUR | OnKure Therapeutics, Inc. | 1,438,456 | $6,559,359 | |
| — | 273,181 | $5,805,096 | ||
| RACC | Research Alliance Corp III | 500,000 | $5,350,000 | |
| IMA | ImageneBio, Inc. | 282,004 | $1,663,823 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Added | 1,523,022 | $49,429,679 | 7.85% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Reduced | 1,573,220 | $38,166,317 | 6.06% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Added | 1,063,234 | $33,757,679 | 5.36% | |
| TRAX |
First Tracks Biotherapeutics, Inc.
Healthcare
|
NEW | 1,514,000 | $30,461,680 | 4.84% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
Added | 2,227,917 | $29,631,296 | 4.70% | |
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
NEW | 512,000 | $29,296,640 | 4.65% | |
| DSGN |
Design Therapeutics, Inc.
Healthcare
|
Added | 2,001,282 | $28,958,550 | 4.60% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Reduced | 440,000 | $26,558,400 | 4.22% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Reduced | 223,312 | $26,143,135 | 4.15% | |
| INSM |
INSMED Inc
Healthcare
|
NEW | 230,331 | $24,557,891 | 3.90% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Reduced | 288,089 | $24,542,301 | 3.90% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Added | 1,110,000 | $24,264,600 | 3.85% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Reduced | 714,885 | $22,483,133 | 3.57% | |
| KLRA |
Kailera Therapeutics, Inc.
Healthcare
|
NEW | 984,786 | $21,694,835 | 3.44% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Reduced | 115,750 | $21,677,660 | 3.44% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Added | 9,051,318 | $18,374,175 | 2.92% | |
| INCY |
Incyte Corp
Healthcare
|
NEW | 155,000 | $17,570,800 | 2.79% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
NEW | 891,881 | $16,481,960 | 2.62% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
NEW | 750,000 | $14,602,500 | 2.32% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
Added | 515,335 | $12,883,375 | 2.05% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 2,571,478 | $12,008,802 | 1.91% | |
| IRD |
Opus Genetics, Inc.
Healthcare
|
Added | 2,743,658 | $11,276,434 | 1.79% | |
| SLGL |
Sol-Gel Technologies Ltd.
Healthcare
|
Added | 139,445 | $10,338,452 | 1.64% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
NEW | 1,443,333 | $10,247,664 | 1.63% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Added | 4,134,969 | $10,130,674 | 1.61% | |
| IVA |
Inventiva S.A.
Healthcare
|
Held | 2,657,997 | $10,047,228 | 1.60% | |
| CAMP |
Camp4 Therapeutics Corp
Healthcare
|
Reduced | 1,932,937 | $8,446,934 | 1.34% | |
| ALT |
Altimmune, Inc.
Healthcare
|
NEW | 2,660,000 | $8,086,400 | 1.28% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Held | 1,419,000 | $7,875,450 | 1.25% | |
| PMN |
ProMIS Neurosciences Inc.
Healthcare
|
Held | 557,103 | $7,331,475 | 1.16% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
NEW | 1,438,456 | $6,559,359 | 1.04% | |
|
|
NEW | 273,181 | $5,805,096 | 0.92% | ||
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 500,000 | $5,350,000 | 0.85% | |
| VTVT |
vTv Therapeutics Inc.
Healthcare
|
Reduced | 85,192 | $3,207,478 | 0.51% | |
| IMA |
ImageneBio, Inc.
Healthcare
|
NEW | 282,004 | $1,663,823 | 0.26% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.